OTCMKTS:ATRX Adhera Therapeutics (ATRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Adhera Therapeutics Stock (OTCMKTS:ATRX) 30 days 90 days 365 days Advanced Chart Get Adhera Therapeutics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume11,064 shsMarket Capitalization$1,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAdhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.Read More… Receive ATRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adhera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRX Stock News HeadlinesAdhera Therapeutics Inc (ATRX)January 30, 2024 | investing.comATRX Adhera Therapeutics, Inc.August 24, 2023 | seekingalpha.comAI Boom Takes a Shocking Turn…The AI “Gold Rush” is Here… History's repeating itself — but this time, the shovels are digital. May 14, 2025 | Crypto 101 Media (Ad)Intensity Therapeutics upsizes proposed IPO to $15M from $8MMay 22, 2023 | seekingalpha.comAdhera Therapeutics, Inc. (ATRX)February 27, 2023 | finance.yahoo.comAdhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 DiabetesJanuary 25, 2023 | finance.yahoo.comCGTX Cognition Therapeutics, Inc.January 18, 2023 | seekingalpha.comAdhera Therapeutics files for Nasdaq uplisting, $35M offeringDecember 5, 2022 | seekingalpha.comSee More Headlines ATRX Stock Analysis - Frequently Asked Questions When did Adhera Therapeutics' stock split? Adhera Therapeutics shares reverse split on Thursday, October 6th 2022. The 1-20 reverse split was announced on Thursday, October 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Adhera Therapeutics? Shares of ATRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adhera Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adhera Therapeutics investors own include Ashford Hospitality Trust (AHT), Peabody Energy (BTU), PlayAGS (AGS), Assertio (ASRT), Astronics (ATRO), CONSOL Coal Resources (CCR) and Acorda Therapeutics (ACOR). Company Calendar Today5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ATRX CIK737207 Webadherathera.com Phone919-518-3748Fax206-830-9424Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares11,627,000Free Float8,348,000Market Cap$1,000.00 OptionableNot Optionable Beta4.03 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:ATRX) was last updated on 5/14/2025 by MarketBeat.com Staff From Our PartnersAI Boom Takes a Shocking Turn…The AI “Gold Rush” is Here… History's repeating itself — but this time, the shovels are digital. Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Musk’s Next Big BetCancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adhera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adhera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.